Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  208.17
-2.47 (-1.17%)
AAPL  272.50
-1.73 (-0.63%)
AMD  203.24
-7.62 (-3.61%)
BAC  52.29
+0.60 (1.16%)
GOOG  303.98
-9.05 (-2.89%)
META  651.26
-2.43 (-0.37%)
MSFT  402.34
+1.74 (0.43%)
NVDA  186.60
-8.96 (-4.58%)
ORCL  148.06
+0.17 (0.11%)
TSLA  408.20
-9.20 (-2.20%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.